Progression of Late-Onset Stargardt Disease | Zendy

Stanley Lambertus | Zendy; Moritz Lindner | Zendy; Nathalie M. Bax | Zendy; Matthias M. Mauschitz | Zendy; Jennifer Nadal | Zendy; Matthias Schmid | Zendy; Steffen Schmitz-Valckenberg | Zendy; Anneke I. den Hollander | Zendy; Bernhard H. F. Weber | Zendy; Frank G. Holz | Zendy; Gert Jan van der Wilt | Zendy; Monika Fleckenstein | Zendy; Carel B. Hoyng | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Progression of Late-Onset Stargardt Disease

Author(s) -

Stanley Lambertus,

Moritz Lindner,

Nathalie M. Bax,

Matthias M. Mauschitz,

Jennifer Nadal,

Matthias Schmid,

Steffen Schmitz-Valckenberg,

Anneke I. den Hollander,

Bernhard H. F. Weber,

Frank G. Holz,

Gert Jan van der Wilt,

Monika Fleckenstein,

Carel B. Hoyng

Publication year - 2016

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.16-19833

Subject(s) - stargardt disease , medicine , abca4 , atrophy , visual acuity , confidence interval , hazard ratio , ophthalmology , macular degeneration , pathology , phenotype , biochemistry , chemistry , gene

Identification of sensitive biomarkers is essential to determine potential effects of emerging therapeutic trials for Stargardt disease. This study aimed to describe the natural history of late-onset Stargardt, and demonstrates the accuracy of retinal pigment epithelium (RPE) atrophy progression as an outcome measure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research